Bernard Pau

CDP Capital Private Equity (CDPQ) is a private equity subsidiary of The Caisse de dépôt et placement du Québec founded in 1995. The firm is headquartered in Montréal with additional office in London.

Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada.

CTI Life Sciences Fund LP invests in high quality emerging life sciences companies located in Canada. The fund targets companies operating in the fields of pharmaceuticals and biotechnology companies. It provides financing for seed, early and development stage capital requirements. It also act as lead investor.

BioRéalités develops novel therapeutic and diagnostic tools to improve the life of colorectal cancer patients. The company was created as an SAS in february 2007, and has been furthering the work of its founders in the field of oncology, with a particular focus on the characterization of a novel target for colorectal cancer therapy. BioRéalités currently employs 13 staff and recently moved in their own facility, which include a 200 m2 laboratory area. The company has been granted an exclusive international license to exploit a PCT patent lodged by INSERM, CNRS, and the University of Montpellier 1 in 2006.

CDP Capital Technology Ventures is a venture capital firm that invests in technology companies. The firm provides funding for companies in various stages of development, from early-stage startups to established businesses. CDP Capital Technology Ventures focuses on companies in the information technology, telecommunications, and life sciences sectors. The firm is a subsidiary of Caisse de dépôt et placement du Québec, one of Canada's largest institutional fund managers, and ultimately controlled by the Province of Québec.

The Ontario Bioscience Industry Organization is a membership organization that engages in strategy, programming, policy development, and advocacy. The non-profit company is based in Toronto, Canada. The Canadian company was founded by Simon Goulet. Maura Campbell has been the CEO of the company since 2021.

The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada.